AKT1 and cancer: This suggests that YM-1 can cause toxicity specific to cancer cells, similar to the parent compound MKT-077, but that YM-1 does so by reducing pro-survival kinases like Akt, potentially leading to alterations in resistance mechanisms in refractory tumors.